Clinical experience with endothelin antagonists

American Journal of Hypertension

Volumn 11, Issue 4 SUPPL. 2, 1998, Pages 71S-79S

  Webb, David J ^a   Strachan, Fiona E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bosentan; Endothelin receptor antagonist; Endothelin 1

Indexed keywords

BOSENTAN; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST;

ATHEROGENESIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; DRUG POTENCY; ENDOTHELIUM CELL; HEART FAILURE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

AMINO ACID SEQUENCE; ANIMALS; CARDIAC OUTPUT, LOW; CARDIOVASCULAR PHYSIOLOGY; CARDIOVASCULAR SYSTEM; CHRONIC DISEASE; ENDOTHELIN-1; ENDOTHELINS; HUMANS; HYPERTENSION;

EID: 0031780881     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00003-X     Document Type: Article

References (48)

1. Yanagisawa M, Kurihara H, Kimura S, et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.
2. Palmer R, Ferrige A, Moncada S: Nitric oxide accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-526.
3. Inoue A, Yanagisawa M, Kimura S: The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-2867.
4. Gray G, Webb D: The therapeutic potential of endothelin receptor antagonists in cardiovascular disease. Pharmacol Ther 1996;72:109-148.
5. Yoshimoto S, Ishizaki Y, Sasaki T, et al: Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 1991;22: 378-383.
6. Dupuis J, Stewart D, Cernacek P, Gosselin G: Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996; 94:1578-1584.
7. A receptors in humans? Trends Pharmacol Sci 1994;15:9-11.
8. Molenaar P, O'Reilly G, Sharkey A, et al: Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circulation 1993;72:526-538.
9. Hosoda K, Nakao K, Arai H, et al: Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991;287:23-26.
10. Ogawa Y, Nakao K, Arai H, et al: Molecular cloning of a non-isopeptide-selective human endothelin receptor. Biochem Biophys Res Commun 1991;178:248-255.
11. Bax W, Saxena P: The current endothelin receptor classification: time for reconsideration? Trends Pharmacol Sci 1994;15:379-386.
12. Rubanyi G, Polokoff M: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.
13. Vierhapper H, Wagner P, Nowotny P, Walhausl W: Effect of endothelin in man. Circulation 1990;81:1415-1418.
14. Pernow J, Kaijser L, Lundberg J, Ahlborg G: Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996;94:2077-2082.
15. Wagner O, Vierhapper H, Gasic S, et al: Regional effects and clearance of endothelin-1 across pulmonary and splanchnic circulation. Eur J Clin Invest 1992;22:277-282.
16. Clarke J, Benjamin N, Larkin S, et al: Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol 1989;257:H2033-H2035.
17. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995; 92:357-363.
18. B receptor agonists on forearm resistance and capacitance vessels in vivo. Br J Clin Pharmacol 1998;45:195P.
19. Haynes W, Webb D: Venoconstriction to endothelin-1 in humans: the role of calcium and potassium channels. Am J Physiol 1993;265:H1676-H1681.
20. Opgenorth T, Wu-Wong J, Shiosaki K: Endothelin-converting enzymes. FASEB J 1992;6:2653-2659.
21. Haynes W, Webb D: Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852-854.
22. A receptor. Life Sci 1992;50:247-255.
23. B. Biochem Biophys Res Commun 1994;200:1708-1712.
24. Haynes W, Ferro C, O'Kane K, et al: Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation 1996;93: 1860-1870.
25. Wenzel R, Noll G, Luscher T: Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994;23:581-586.
26. de Berrazueta J, Bhagat K, Vallance P, MacAllister R: Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol 1997;44:569-571.
27. Ishikawa K, Ihara M, Noguchi K, et al: Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. Proc Natl Acad Sci USA 1994;91:4892-4896.
28. Verhaar M, Strachan F, Newby D, et al: Endothelin-A receptor antagonist mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (in press).
29. Webb D: The pharmacology of human blood vessels in vivo. J Vasc Res 1995;32:2-15.
30. B-mediated blood pressure responses in rats. J Pharmacol Exp Ther 1994;270:728-733.
31. Ferro C, Haynes W, Johnston N, et al: The peptide endothelin antagonist, TAK-044, produces sustained inhibition of endothelin mediated arteriolar vasoconstriction in man. Br J Clin Pharmacol 1997;44:377-383.
32. Ferro C, Webb D: The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 1996;51:12-27.
33. Lerman A, Edwards B, Hallett J, et al: Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.
34. Zeiher A, Ihling C, Pistorius K, et al: Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994; 344:1405-1406.
35. Banting J, Friberg P, Adams M: Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction. J Hypertens 1996; 14:975-981.
36. Munzel T, Giaid A, Kurz S. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA 1995;92:5244-5248.
37. Dubin D, Pratt R, Dzau V: Endothelin, a potent vasoconstrictor, is a vascular smooth muscle mitogen. J Vasc Med Biol 1989;1:150-154.
38. Battastini B, Chailler P, D'Orleans-Juste P, et al: Growth regulatory properties of endothelins. Peptides 1993;14: 385-399.
39. Dargie H, McMurray J: Diagnosis and management of heart failure. Br Med J 1994;308:321-328.
40. Pacher R, Bergler-Klein J, Globits S, et al: Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am J Cardiol 1993;71:1293-1299.
41. Cody R, Haas G, Binkley P, et al: Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992;85:504-509.
42. Krum H, Goldsmith R, Wilshire-Clement M, et al: Importance of endothelin in the exercise intolerance of heart failure in humans. Mayo Clin Proc 1992;67:719-724.
43. Galatius-Jensen S, Wroblewski H, Emmeleuth C, et al: Plasma endothelin-1 in chronic heart failure: a predictor of cardiac death? J Cardiac Failure 1996;2:71-76.
44. Pacher R, Stanek B, Hulsmann M, et al: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-641.
45. Omland T, Lie R, Aakvaag A, et al: Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89:1573-1579.
46. Kiowski W, Sutsch G, Hunziker P, et al: Evidence of endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-736.
47. Webb D: Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure: endothelin antagonism in heart failure (editorial). Circulation 1995;92: 3372.
48. A receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996;94: 2131-2137.